Michele W.L. Teng

22.5k citations

95 papers · 15.0k indexed · 9 hit papers · h-index 56

Oncology top 0.1%
Immunology top 0.1%
Molecular Biology top 2%
Pulmonary and Respiratory Medicine top 1%
Cancer Research top 1%

Co-authors: Mark J. Smyth Shin Foong Ngiow Jake S. O’Donnell Antoni Ribas Arabella Young Maya Kansara David M. Thomas Dipti Vijayan
Topics: CAR-T cell therapy research (43 papers)Immune Cell Function and Interaction (43 papers)Immunotherapy and Immune Responses (42 papers)
Cited by: Immunology Oncology Physiology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Journal of Clinical Investigation
Partner nations: Australia United States Japan

In The Last Decade

Michele W.L. Teng

94 papers receiving 14.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer immunoediting and resistance to T cell-based immunotherapy

2018 1.3k citations Jake S. O’Donnell, Michele W.L. Teng et al. profile →
Classifying Cancers Based on T-cell Infiltration and PD-L1

2015 1.1k citations Michele W.L. Teng, Shin Foong Ngiow et al. Cancer Research profile →
Translational biology of osteosarcoma

2014 978 citations Maya Kansara, Michele W.L. Teng et al. profile →
Combination cancer immunotherapies tailored to the tumour microenvironment

2015 738 citations Mark J. Smyth, Shin Foong Ngiow et al. profile →
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases

2015 639 citations Michele W.L. Teng, Mark J. Smyth et al. profile →
Targeting immunosuppressive adenosine in cancer

2017 608 citations Dipti Vijayan, Arabella Young et al. profile →
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

2016 569 citations Jing Liu, Stephen J. Blake et al. Cancer Discovery profile →
De-novo and acquired resistance to immune checkpoint targeting

2017 555 citations Michele W.L. Teng et al. profile →
Resistance to PD1/PDL1 checkpoint inhibition

2016 429 citations Jake S. O’Donnell, Michele W.L. Teng et al. profile →

Peers

Countries citing papers authored by Michele W.L. Teng

Since Specialization

Citations

This map shows the geographic impact of Michele W.L. Teng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michele W.L. Teng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michele W.L. Teng more than expected).

Fields of papers citing papers by Michele W.L. Teng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michele W.L. Teng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michele W.L. Teng. The network helps show where Michele W.L. Teng may publish in the future.

Co-authorship network of co-authors of Michele W.L. Teng

This figure shows the co-authorship network connecting the top 25 collaborators of Michele W.L. Teng. A scholar is included among the top collaborators of Michele W.L. Teng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michele W.L. Teng. Michele W.L. Teng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Control of Metastases via Myeloid CD39 and NK Cell Effector Function 2020 ·Cancer Immunology Research ·Juming Yan,Xian-Yang Li,Amelia Roman Aguilera,Christos Xiao,Célia Jacoberger-Foissac,Bianca Nowlan,Simon C. Robson,Courtney Beers,Achim K. Moesta,Nishamol Geetha,Michele W.L. Teng,Mark J. Smyth	63
2	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23 2019 ·Cancer Discovery ·Maya Kansara,(unknown),Puiyi Pang,Aurélie Dutour,Lisa Mirabello,Francine Acher,Jean‐Philippe Pin,Elizabeth G. Demicco,Juming Yan,Michele W.L. Teng,Mark J. Smyth,David M. Thomas	35
3	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN) 2019 ·Trials ·Elizabeth Ahern,(unknown),E Ballard,Michele W.L. Teng,William C. Dougall,Mark J. Smyth,(unknown),Rishendran Naidoo,Amanda Goldrick,Brett Hughes	22
4	MAIT Cells Promote Tumor Initiation, Growth, and Metastases via Tumor MR1 2019 ·Cancer Discovery ·Juming Yan,Stacey Allen,Elizabeth S. McDonald,Indrajit Das,Jeffrey Y. W. Mak,Ligong Liu,David P. Fairlie,Bronwyn S. Meehan,Zhenjun Chen,Alexandra J. Corbett,Antiopi Varelias,Mark J. Smyth,Michele W.L. Teng	106
5	Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23 2018 ·Cancer Immunology Research ·Juming Yan,Stacey Allen,Dipti Vijayan,Xian-Yang Li,Heidi Harjunpää,Kazuyoshi Takeda,Jing Liu,J. Daniel,Mark J. Smyth,Michele W.L. Teng	13
6	CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity 2018 ·OncoImmunology ·Amelia Roman Aguilera,Viviana P. Lutzky,Deepak Mittal,Xian-Yang Li,Kimberley Stannard,Kazuyoshi Takeda,Günter Bernhardt,Michele W.L. Teng,William C. Dougall,Mark J. Smyth	42
7	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell–Rich Tumor 2016 ·Cancer Research ·Shin Foong Ngiow,Arabella Young,Stephen J. Blake,Geoffrey R. Hill,Hideo Yagita∥,Michele W.L. Teng,Alan J. Korman,Mark J. Smyth	72
8	Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer 2016 ·Cancer Research ·Jing Liu,Stephen J. Blake,Heidi Harjunpää,Kirsten A. Fairfax,Michelle C.R. Yong,Stacey Allen,Holbrook E. Kohrt,Kazuyoshi Takeda,Mark J. Smyth,Michele W.L. Teng	76
9	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy 2016 ·Cancer Discovery ·Stephen J. Blake,Kimberley Stannard,Jing Liu,Stacey Allen,Michelle C.R. Yong,Deepak Mittal,Amelia Roman Aguilera,John J. Miles,Viviana P. Lutzky,Lucas Ferrari de Andrade,Ludovic Martinet,Marco Colonna,Kazuyoshi Takeda,Florian Kühnel,Engin Gürlevik,Günter Bernhardt,Michele W.L. Teng,Mark J. Smyth	187
10	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting 2016 ·Clinical Cancer Research ·Clare Y. Slaney,Bianca von Scheidt,Alexander J. Davenport,Paul A. Beavis,Jennifer A. Westwood,Sherly Mardiana,David C. Tscharke,Sarah Ellis,H. Miles Prince,Joseph A. Trapani,Ricky W. Johnstone,Mark J. Smyth,Michele W.L. Teng,(unknown),Zhiya Yu,Steven A. Rosenberg,Nicholas P. Restifo,Paul J. Neeson,Phillip K. Darcy,Michael H. Kershaw	89
11	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Diseasebreakdown → 2016 ·Cancer Discovery ·Jing Liu,Stephen J. Blake,Michelle C.R. Yong,Heidi Harjunpää,Shin Foong Ngiow,Kazuyoshi Takeda,Arabella Young,Jake S. O’Donnell,Stacey Allen,Mark J. Smyth,Michele W.L. Teng	569
12	Combined Anti-CD40 and Anti–IL-23 Monoclonal Antibody Therapy Effectively Suppresses Tumor Growth and Metastases 2014 ·Cancer Research ·Bianca von Scheidt,(unknown),Michelle C.R. Yong,Yu Zhang,Jennifer E. Towne,Mark J. Smyth,Michele W.L. Teng	30
13	Cancer immunoediting by the innate immune system in the absence of adaptive immunity 2012 ·The Journal of Experimental Medicine ·Timothy E. O’Sullivan,Robert Saddawi‐Konefka,William Vermi,Catherine Koebel,Cora D. Arthur,J. Michael White,Ravindra Uppaluri,Daniel M. Andrews,Shin Foong Ngiow,Michele W.L. Teng,Mark J. Smyth,Robert D. Schreiber,Jack D. Bui	257
14	Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State 2012 ·Cancer Research ·Michele W.L. Teng,Matthew D. Vesely,Helene Duret,Nicole M. McLaughlin,Jennifer E. Towne,Robert D. Schreiber,Mark J. Smyth	88
15	Anti-TIM3 Antibody Promotes T Cell IFN-γ–Mediated Antitumor Immunity and Suppresses Established Tumors 2011 ·Cancer Research ·Shin Foong Ngiow,Bianca von Scheidt,Hisaya Akiba,Hideo Yagita∥,Michele W.L. Teng,Mark J. Smyth	469
16	CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis 2011 ·Cancer Research ·John Stagg,Upulie Divisekera,Helene Duret,Tim Sparwasser,Michele W.L. Teng,Phillip K. Darcy,Mark J. Smyth	320
17	Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth 2010 ·Cancer Research ·Michele W.L. Teng,Shin Foong Ngiow,Bianca von Scheidt,Nicole M. McLaughlin,Tim Sparwasser,Mark J. Smyth	149
18	Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion 2010 ·Cancer Research ·Michele W.L. Teng,Jeremy B. Swann,Bianca von Scheidt,Janelle Sharkey,Nadeen Zerafa,Nicole M. McLaughlin,Tomoyuki Yamaguchi,Shimon Sakaguchi,Phillip K. Darcy,Mark J. Smyth	58
19	Interleukin 21 Enhances Antibody-Mediated Tumor Rejection 2008 ·Cancer Research ·Mark J. Smyth,Michele W.L. Teng,Janelle Sharkey,Jennifer A. Westwood,Nicole M. Haynes,Hideo Yagita∥,Kazuyoshi Takeda,Pallavur V. Sivakumar,Michael H. Kershaw	23
20	Combined Natural Killer T-Cell–Based Immunotherapy Eradicates Established Tumors in Mice 2007 ·Cancer Research ·Michele W.L. Teng,Jennifer A. Westwood,Phillip K. Darcy,Janelle Sharkey,Moriya Tsuji,Richard W. Franck,Steven A. Porcelli,Gurdyal S. Besra,Kazuyoshi Takeda,Hideo Yagita∥,Michael H. Kershaw,Mark J. Smyth	55

About Michele W.L. Teng

Michele W.L. Teng is a scholar working on Immunology, Oncology and Physiology, having authored 95 papers that have together received 15.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (43 papers), Immune Cell Function and Interaction (43 papers) and Immunotherapy and Immune Responses (42 papers). The work is most often cited by research in Immunology (8.3k citations), Oncology (9.2k citations) and Physiology (1.0k citations). Michele W.L. Teng has collaborated with scholars based in Australia, United States and Japan. Frequent co-authors include Mark J. Smyth, Shin Foong Ngiow, Jake S. O’Donnell, Antoni Ribas, Arabella Young, Maya Kansara, David M. Thomas, Dipti Vijayan, Stephen J. Blake and Phillip K. Darcy. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact